Analyst Coverage
Diamond Equity Research
Imugene Limited – Announces Up to A$46 Million Financing, Achieves First Intratumoural onCARlytics Dosing Milestone, and Opens First Australian Azer-cel Trial Site for Relapsed or Refractory DLBCL
Diamond Equity Research
Sustained Momentum with Key Clinical Advancements and Robust Financial Profile, With Numerous Upcoming Potential Catalysts
Diamond Equity Research
Receives Orphan Drug Designation for Bile Tract CancerTherapy and Reports Encouraging Blood Cancer Trial Outcomes
Lodge Partners
Research Report Imugene Limited (ASX: IMU)
Bioshares
Imugene Delivers Positive Early Data with Azer-Cel Technology Acquired Last Year
Roth Capital Partners
IMU: Azer-Cel Showing CRs In DLBCL Patients In Phase 1b Trial
Diamond Equity Research
IMU: Quarterly Report Highlights Significant Progress in Multiple Candidates, Strong Balance Sheet, and Numerous Upcoming Potential Clinical Catalysts
Roth Capital Partners
IMU: Phase 1 OASIS Solid Tumor Trial Starts Combination Therapy Dosing
Diamond Equity Research
IMU: Q3 FY2024 Update, Intellectual Property Milestones, and Meaningful Clinical Trial Advancements Anticipated in 2H 2024
Roth Capital Partners
IMU: General Quarterly Business Update, 2H24 To Be Rich In Clinical Data
Bell Potter
Imugene Core Assets Progressing Nicely
Diamond Equity Research